A mouse model repository for cancer biomarker discovery

被引:21
作者
Kelly-Spratt, Karen S. [1 ]
Kasarda, A. Erik [1 ]
Igra, Mark [1 ]
Kemp, Christopher J. [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
关键词
early detection; repository; biomarker; proteomics; plasma;
D O I
10.1021/pr800210b
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Early detection of cancer using biomarkers obtained from blood or other easily accessible tissues would have a significant impact on reducing cancer mortality. However, identifying new blood-based biomarkers has been hindered by the dynamic complexity of the human plasma proteome, confounded by genetic and environmental variability, and the scarcity of high quality controlled samples. In this report, we discuss a new paradigm for biomarker discovery through the use of mouse models. Inbred mouse models of cancer recapitulate many critical features of human cancer, while eliminating sources of environmental and genetic variability. The ability to collect samples from highly matched cases and controls under identical conditions further reduces variability which is critical for successful biomarker discovery. We describe the establishment of a repository containing tumor, plasma, urine, and other tissues from 10 different mouse models of human cancer, including two breast, two lung, two prostate, two gastrointestinal, one ovarian, and one skin tumor model. We present the overall design of this resource and its potential use by the research community for biomarker discovery.
引用
收藏
页码:3613 / 3618
页数:6
相关论文
共 37 条
[1]   The human plasma proteome - History, character, and diagnostic prospects [J].
Anderson, NL ;
Anderson, NG .
MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) :845-867
[2]   The performance of screening tests for ovarian cancer: results of a systematic review [J].
Bell, R ;
Petticrew, M ;
Sheldon, T .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1998, 105 (11) :1136-1147
[3]   A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing [J].
Chace, DH ;
Kalas, TA .
CLINICAL BIOCHEMISTRY, 2005, 38 (04) :296-309
[4]  
Connolly DC, 2003, CANCER RES, V63, P1389
[5]   Peptidomics for cancer diagnosis: Present and future [J].
Diamandis, Eleftherios P. .
JOURNAL OF PROTEOME RESEARCH, 2006, 5 (09) :2079-2082
[6]   The case for early detection [J].
Etzioni, R ;
Urban, N ;
Ramsey, S ;
McIntosh, M ;
Schwartz, S ;
Reid, B ;
Radich, J ;
Anderson, G ;
Hartwell, L .
NATURE REVIEWS CANCER, 2003, 3 (04) :243-252
[7]  
Etzioni R, 2002, J NATL CANCER I, V94, P981
[8]   Body fluid proteomics for biomarker discovery: Lessons from the past hold the key to success in the future [J].
Good, David M. ;
Thongboonkerd, Visith ;
Novak, Jan ;
Bascands, Jean-Loup ;
Schanstra, Joost P. ;
Coon, Joshua J. ;
Dominiczak, Anna ;
Mischak, Harald .
JOURNAL OF PROTEOME RESEARCH, 2007, 6 (12) :4549-4555
[9]   PROSTATE-CANCER IN A TRANSGENIC MOUSE [J].
GREENBERG, NM ;
DEMAYO, F ;
FINEGOLD, MJ ;
MEDINA, D ;
TILLEY, WD ;
ASPINALL, JO ;
CUNHA, GR ;
DONJACOUR, AA ;
MATUSIK, RJ ;
ROSEN, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3439-3443
[10]   The US food and drug administration perspective on cancer biomarker development [J].
Gutman, Steven ;
Kessler, Larry G. .
NATURE REVIEWS CANCER, 2006, 6 (07) :565-571